Abstract:Colorectal cancer (CRC) is the third leading cause of cancer mortality in the United States, with an estimated 52,000 deaths in 2023. Though significant progress has been made in both diagnosis and treatment of CRC in recent years, genetic heterogeneity of CRC-the culprit for possible CRC relapse and drug resistance, is still an insurmountable challenge. Thus, developing more effective therapeutics to overcome this challenge in new CRC treatment strategies is imperative. Genetic and epigenetic changes are well recognized to be responsible for the stepwise development of CRC malignancy. In this review, we focus on detailed genetic alteration information about the nuclear factor (NF)-κB signaling, including both NF-κB family members, and their regulators, such as protein arginine methyltransferase 5 (PRMT5), and outer dynein arm docking complex subunit 2 (ODAD2, also named armadillo repeat-containing 4, ARMC4), etc., in CRC patients. Moreover, we provide deep insight into different CRC research models, with a particular focus on patient-derived xenografts (PDX) and organoid models, and their potential applications in CRC research. Genetic alterations on NF-κB signaling components are estimated to be more than 50% of the overall genetic changes identified in CRC patients collected by cBioportal for Cancer Genomics; thus, emphasizing its paramount importance in CRC progression. Consequently, various genetic alterations on NF-κB signaling may hold great promise for novel therapeutic development in CRC. Future endeavors may focus on utilizing CRC models (e.g., PDX or organoids, or isogenic human embryonic stem cell (hESC)-derived colonic cells, or human pluripotent stem cells (hPSC)-derived colonic organoids, etc.) to further uncover the underpinning mechanism of these genetic alterations in NF-κB signaling in CRC progression. Moreover, establishing platforms for drug discovery in dishes, and developing Biobanks, etc., may further pave the way for the development of innovative personalized medicine to treat CRC in the future.

Genetic and biological hallmarks of colorectal cancer

An Overview of Molecular Profiles in Ulcerative Colitis–Related Cancer

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Epigenetics of colorectal cancer: biomarker and therapeutic potential

Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies

Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis

The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer

Molecular Network of Colorectal Cancer and Current Therapeutic Options

Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials

Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine

Evolutionary mechanism unifies the hallmarks of cancer

Integrating Hallmarks of Cancer

Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors

Genetic Alterations of NF-κB and Its Regulators: A Rich Platform to Advance Colorectal Cancer Diagnosis and Treatment

A Multidimensional Analysis of Genes Mutated in Breast and Colorectal Cancers

Hallmarks of Cancer: New Dimensions.

Colorectal Cancers: An Update on Their Molecular Pathology

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

The Epigenetic Hallmarks of Cancer

Hallmarks of cancer—the new testament

Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review